Newsletter | January 16, 2020

01.16.20 -- 2020 Biosimilar Advancements To Watch

 
Featured Editorial
Biosimilar Industry Advancements To Watch In 2020
 
By Anna Rose Welch, editor, Biosimilar Development

Multibiosimilar competition in the U.S. oncology space, as well as the FDA’s regulatory progress toward a more competitive insulin market, are popular topics the Biosimilar Development editorial board is watching. But these are hardly the only big 2020 events to note in this progressing industry.

A Biopharma Year In Review: And A Look Ahead To 2020
 
By K. John Morrow, Jr. and Eric S. Langer

The industry has shown surprising resilience and consistency, emerging relatively unscathed from the recession at the beginning of the past decade. Capacity and expansion were relatively unaffected and continue to draw investors seeking healthy returns and a recession-resistant risk profile.

Inside The FDA’s Latest Biosimilar “Game-Changing” Guidance
 
By Anna Rose Welch, editor, Biosimilar Development

Overall, there are three broad takeaways to both celebrate and consider about the FDA’s latest clarification of the biosimilar regulatory pathway as it relates to insulin biosimilars.

Industry Insights
Can You Trust A Machine For Downstream Bioprocess Buffer Preparation?
Article | By Enrique Carredano, GE Healthcare Life Sciences

There is a limit to how many stainless-steel tanks you can squeeze into a biomanufacturing facility. Is automated buffer preparation a solution to the dilemma of balancing increased production capacity against limited footprint expansion alternatives?

Solutions
ChemiDoc Imaging System
Bio-Rad Laboratories, Inc.
Connect With Biosimilar Development:
      Twitter